Israeli Biotech Company Granted US Patent for Kidney Cancer Test

Israeli biotech Rosetta Genomics has been granted a US patent for its ability to differentiate between four types of kidney cancer.

Israeli biotech Rosetta Genomics has been granted a US patent for its gene signature method of distinguishing four different types of kidney cancer. The molecular diagnostic test recognizes the profile of 29 microRNAs that are expressed in patients with renal cancer.
http://www.rosettagx.com/files/press_releases/2016/012516_ROSG_Kidney_Tumor_Classification_Patent_FINAL.pdf

By: Michael Ordman

Click here for all of this week’s Good News from Israel.

Do You Love Israel? Make a Donation - Show Your Support!

Donate to vital charities that help protect Israeli citizens and inspire millions around the world to support Israel too!

Now more than ever, Israel needs your help to fight and win the war -- including on the battlefield of public opinion.

Antisemitism, anti-Israel bias and boycotts are out of control. Israel's enemies are inciting terror and violence against innocent Israelis and Jews around the world. Help us fight back!

STAND WTH ISRAEL - MAKE A DONATION TODAY!